```markdown
---
title: "NDA 208574 – Complete Response Letters – Romidepsin Injection"
sponsor:
  name: "Teva Pharmaceuticals USA Inc."
  contacts:
    - name: "Scott Tomsky"
      title: "Vice President, Regulatory Affairs, US Generics"
      address: "425 Privet Road, Horsham, PA 19044"
    - name: "Joann Stavole"
      title: "Senior Director, Regulatory Affairs, US Generics"
      address: "400 Interpace Parkway, Parsippany, NJ 07054"
    - name: "Cory Wohlbach"
      title: "Director, Regulatory Affairs, US Generics"
      address: "425 Privet Road, Horsham, PA 19044"
product:
  name: "Romidepsin Injection"
  dosage: "10 mg/2 mL (5 mg/mL)"
application_numbers:
  - NDA 208574
application_dates:
  - "August 18, 2015"
  - "December 29, 2016"
amendment_dates:
  - "May 29, 2019"
  - "December 29, 2016"
manufacturing_facilities:
  - name: "TEVA PARENTERAL MEDICINES, INC."
    fei: "2027158"
  - name: "Teva Pharmaceutical Works Private Limited Company"
    location: "Gödöllő, Hungary"
    fei: "3002875215"
status: "Complete Response – Application Not Approved in Current Form"
fda_contacts:
  - name: "Albert Deisseroth, MD, PhD"
    title: "Supervisory Associate Deputy Director"
  - name: "Edvardas Kaminskas, MD"
    title: "Deputy Director"
---

## Critical Data

| Field                     | Details                                                      |
|--------------------------|--------------------------------------------------------------|
| NDA Number               | NDA 208574                                                   |
| Sponsor                  | Teva Pharmaceuticals USA Inc.                                |
| Product                  | Romidepsin Injection, 10 mg/2 mL (5 mg/mL)                   |
| Application Dates        | August 18, 2015; December 29, 2016                           |
| Amendments Received      | May 29, 2019; December 29, 2016                              |
| Manufacturing Facilities | - TEVA PARENTERAL MEDICINES, INC. (FEI 2027158) <br>- Teva Pharmaceutical Works Private Ltd., Gödöllő, Hungary (FEI 3002875215) |
| Status                   | Not approved in current form; multiple complete response letters issued |
| FDA Contacts             | - Albert Deisseroth, MD, PhD <br>- Edvardas Kaminskas, MD    |

---

# CENTER FOR DRUG EVALUATION AND RESEARCH  
## NDA 208574 – COMPLETE RESPONSE – CLASS 2 RESUBMISSION  

### Sponsor:  
Teva Pharmaceuticals USA Inc.  
Attention: Scott Tomsky  
Vice President, Regulatory Affairs, US Generics  
425 Privet Road  
Horsham, PA 19044  

---

### Application Summary  
- NDA dated: August 18, 2015  
- Amendment received: May 29, 2019  
- Product: Romidepsin Injection solution, 10 mg/2 mL (5 mg/mL)  
- FDA conclusion: Cannot approve the application in its present form  

---

## PRODUCT QUALITY  

During a recent inspection of the TEVA PARENTERAL MEDICINES, INC. (FEI 2027158) manufacturing facility, our investigator conveyed deficiencies to the representatives on site. Resolution of these deficiencies is required before this application may be approved.

---

## PRESCRIBING INFORMATION  

Comments on labeling will be withheld until the application is otherwise adequate.

Resources:  
- PLR Requirements for Prescribing Information  
- Pregnancy and Lactation Labeling Final Rule  
- Selected Requirements for Prescribing Information (SRPI) checklist  

Labeling revisions must:  
- Conform to format regulations using SRPI checklist  
- Include updated content per 21 CFR 314.50(l)(1)(i)  
- Be submitted in Structured Product Labeling (SPL) format  

---

## FACILITY INSPECTIONS  

As noted, deficiencies were identified at:  
- TEVA PARENTERAL MEDICINES, INC. (FEI 2027158)  
Approval is contingent upon their resolution.

---

## SAFETY UPDATE  

Per 21 CFR 314.50(d)(5)(vi)(b), include the following in your response:

1. Describe significant changes or findings in the safety profile.  
2. Incorporate new safety data:  
   - Use same format as original submission  
   - Include tabulated data combined with prior submissions  
   - Compare adverse events frequencies side by side  
   - Separate tables for non-proposed indications  
3. Retabulate premature discontinuation reasons and identify new trends.  
4. Provide case report forms and narrative summaries for:  
   - Every death during clinical trials  
   - Discontinuations due to adverse events  
   - Serious adverse events  
5. Describe any substantial changes in incidence of common, less serious adverse events.  
6. Provide updated exposure information (e.g., number of subjects, person time).  
7. Summarize worldwide safety experience and usage.  
8. Provide English translations of current approved foreign labeling not previously submitted.

---

## OTHER  

You must act within one year of this letter:  
- Resubmit or take actions per 21 CFR 314.110  
- Inaction may result in withdrawal under 21 CFR 314.65  

Resubmission Instructions:  
- Label submission clearly with "RESUBMISSION" in bold  
- Address ALL deficiencies  
- Partial responses will not start a review cycle  

You may request a meeting/teleconference via the FDA draft guidance:  
“Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products”

---

## Contact  

If you have any questions:  
Kimberly Scott  
Regulatory Project Manager  
(240) 402-4560  

---

Sincerely,  
Albert Deisseroth, MD, PhD  
Supervisory Associate Deputy Director  
Division of Hematology Products  
Office of Hematology and Oncology Products  
Center for Drug Evaluation and Research  

---

# NDA 208574 – COMPLETE RESPONSE  

## Sponsor:  
Teva Pharmaceuticals USA Inc.  
Joann Stavole  
Senior Director, Regulatory Affairs, US Generics  
Morris Corporate Center III  
400 Interpace Parkway  
Parsippany, NJ 07054  

---

### Application Summary  
- NDA dated: December 29, 2016  
- Amendment received: December 29, 2016  
- Product: Romidepsin Injection, solution, 10 mg/2 mL (5 mg/mL)  
- FDA conclusion: Cannot approve the application in its current form  

---

## FACILITY INSPECTIONS  

Manufacturing facility:  
- Teva Pharmaceutical Works Private Limited Company  
- Gödöllő, Hungary (FEI 3002875215)  
- Deficiencies observed and must be addressed for continuation  

---

## PRESCRIBING INFORMATION  

No comment on labeling until application is adequate.

Instructions:  
- Reference: PLR Requirements for Prescribing Information, and SRPI checklist  
- Submit revised labeling in SPL format  

---

## SAFETY UPDATE  

Include a comprehensive safety update per 21 CFR 314.50(d)(5)(vi)(b). Requirements identical to previous safety update:

1. Safety profile changes  
2. Incorporate new data  
3. Retabulate discontinuations  
4. Case reports  
5. Event incidence  
6. Exposure data  
7. Global summary  
8. Foreign labeling translations

---

## OTHER  

Action required within one year per 21 CFR 314.110 or risk withdrawal under 21 CFR 314.65.

Resubmission must:  
- Be labeled "RESUBMISSION" in bold  
- Fully address all deficiencies  
- Not submit partial responses  

Meeting requests: Follow March 2015 FDA Draft Guidance  
“Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products”

---

Sincerely,  
Edvardas Kaminskas, MD  
Deputy Director  
Division of Hematology Products  
Office of Hematology and Oncology Products  
Center for Drug Evaluation and Research  

---

# NDA 208574 – COMPLETE RESPONSE  

## Sponsor:  
Teva Pharmaceuticals USA  
Attention: Cory Wohlbach  
Director, Regulatory Affairs, US Generics  
425 Privet Road  
Horsham, PA 19044  

---

### Application Summary  
- NDA dated: August 18, 2015  
- Product: Romidepsin Injection, 10 mg/2 mL (5 mg/mL)  
- FDA conclusion: Cannot approve the application in its present form  

---

## PRODUCT QUALITY  

Response dated March 28, 2016 did not adequately address extractables/leachables from component materials.

Requested:  
- Revised data or studies to support the safety of materials used in manufacturing  

---

## PRESCRIBING INFORMATION  

Instructions:  
- Use SRPI checklist  
- Submit content in SPL format  
- Provide both clean and marked-up Word versions showing all changes  

Proposed changes:

1. Section 2 – Dosage and Administration  
   - Replace symbols such as ≥, ≤ with words  
2. Section 3 – Dosage Forms and Strengths  
   - Clarify vial parameters  
3. Section 16 – Storage and Handling  
   - Ensure consistency with dosage form details  

---

## CARTON AND CONTAINER LABELING  

Submit revised labeling including:

1. Quantitative ingredient details under 21 CFR 201.100(b)(5)  
2. Sterility and route of administration  
3. Visibility and clarity improvements:  
   - State "For intravenous infusion after dilution"  
   - Include dilution instructions on the principal display panel  
   - Clearly indicate "Single Dose Vial"

---

## FACILITY INSPECTIONS  

Facility: Teva Pharmaceutical Works Private Limited Company  
Location: Gödöllő, Hungary (FEI 3002875215)  
Approval dependent on satisfactory resolution of deficiencies

---

## SAFETY UPDATE  

Requirements identical to prior communications per 21 CFR 314.50(d)(5)(vi)(b)

---

## OTHER  

Take action within one year per 21 CFR 314.110 or risk withdrawal under 21 CFR 314.65

Meeting guidance:  
[Formal Meetings Between FDA and Sponsors or Applicants (May 2009)](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM153222.pdf)

---

Sincerely,  
Edvardas Kaminskas, MD  
Deputy Director  
Division of Hematology Products  
Office of Hematology and Oncology Products  
Center for Drug Evaluation and Research  
```